𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A phase I study of intermittent infusion cladribine in patients with solid tumors

✍ Scribed by Ken Kobayashi; Nicholas J. Vogelzang; Sheila M. O'Brien; Richard L. Schilsky; Everett E. Vokes; Mark J. Ratain

Publisher
John Wiley and Sons
Year
1994
Tongue
English
Weight
621 KB
Volume
74
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

A phase I study of gemcitabine and docet
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors
✍ David P. Ryan; Thomas J. Lynch; Michael L. Grossbard; Michael V. Seiden; Charles πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 70 KB πŸ‘ 2 views

A Phase I study was initiated to determine the maximum tolerated dose of weekly gemcitabine combined with monthly, fixed-dose docetaxel. ## METHODS. Patients with metastatic solid tumors were treated with docetaxel, 60 mg/m 2 , on Day 1 every 28 days. Gemcitabine was administered on Days 1, 8, and

Phase I study of a 120-hour continuous i
Phase I study of a 120-hour continuous intravenous infusion of 5-fluorouracil in pediatric patients with recurrent solid tumors: A pediatric oncology group study
✍ Green, Daniel M. ;Krischer, Jeffrey P. ;Bell, Beverly ;Brecher, Martin L. ;Cushi πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 340 KB

## Abstract To determine the maximum tolerated dose of 5‐fluorouracil administered as a 120‐hour continuous intravenous infusion to pediatric patients, we performed a phase I study using a starting dosage of 900 mg/m^2^/day. The maximum tolerated dosage (MTD) was 1,100 mg/m^2^/day. At this dosage l

A Phase I study of 9-nitrocamptothecin g
A Phase I study of 9-nitrocamptothecin given concurrently with capecitabine in patients with refractory, metastatic solid tumors
✍ M. Dror Michaelson; David P. Ryan; Charles S. Fuchs; Jeffrey G. Supko; Rocio Gar πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 83 KB πŸ‘ 1 views

## Abstract ## BACKGROUND 9‐Nitrocamptothecin (9‐NC) is an orally available camptothecin analog with antineoplastic activity that results from the inhibition of DNA topoisomerase I. Previous studies have suggested that it has significant clinical efficacy. The primary toxicities of 9‐NC include ga